What is PreActiv?
PreActiv operates at the intersection of clinical medicine and health technology, specifically targeting the prehabilitation sector. The company addresses the systemic challenge where millions of patients undergo major surgery annually without adequate physiological optimization, leading to avoidable complications. Founded by senior NHS clinicians with over 25 years of experience, the firm has developed a scalable, cost-effective digital platform that streamlines the preparation process for surgical patients. By integrating clinical rigor with advanced software engineering, PreActiv provides a robust solution for healthcare providers seeking to improve patient recovery rates and reduce the economic burden of post-operative care.
How much funding has PreActiv raised?
PreActiv has raised a total of $639K across 1 funding round:
Other Financing Round
$639K
Other Financing Round (2024): $639K with participation from Exceptional Ventures
Key Investors in PreActiv
Exceptional Ventures
Exceptional Ventures is a London-based venture capital firm that invests in early-stage companies focused on enhancing human longevity, health, and happiness. Founded in 2022, the firm leverages deep expertise in wellness and care delivery to support innovative founders driving scientifically proven advancements.
What's next for PreActiv?
Looking ahead, PreActiv is poised to transition from its current development phase into a period of rapid operational scaling. The recent capital infusion will likely be directed toward enhancing the platform's algorithmic capabilities and expanding its deployment across diverse clinical settings. As the company continues to refine its prehabilitation protocols, the focus will remain on demonstrating measurable improvements in patient outcomes and cost-efficiency for healthcare systems. With a strong management board and a clear mission to reduce surgical harm, PreActiv is strategically positioned to become a standard-bearer in the digital health landscape, potentially attracting further institutional interest as it proves the efficacy of its model at scale.
See full PreActiv company page
